文献速递消化系统肿瘤

早期肿瘤退缩与缓解深度对RAS野生型转移性结直肠癌帕尼单抗维持治疗结局的影响

Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2020-12-13

结果显示ETS和DoR≥34%均与更长的无进展生存期(PFS)和总生存期(OS)相关,且5-FU/LV联合帕尼单抗维持治疗的PFS获益独立于ETS和DoR状态;但单药帕尼单抗且无ETS或DoR<34%的患者结局极差。ETS和DoR可结合PRESSING panel分层PFS和OS。

要点

  • ETS(≥20%缩小)和DoR≥34%与更长的PFS和OS显著相关。
  • 5-FU/LV联合帕尼单抗维持治疗的PFS获益独立于ETS和DoR状态。
  • 单药帕尼单抗且无ETS或DoR<34%的患者PFS和OS极差。

核心结论

  • ETS和DoR可在治疗中预判基于抗EGFR策略降阶梯治疗的结局。
  • 影像学反应差可能指导患者入组交叉策略试验。

主要发现

  • ETS发生率为67.3%(132例),中位DoR为44.1%。
  • ETS和DoR≥34%均与更长的mPFS(p=0.010和p<0.001)和mOS(p=0.006和p<0.001)相关。
  • 5-FU/LV联合帕尼单抗维持治疗的PFS获益独立于ETS和DoR状态(交互检验无统计学意义)。
  • 单药帕尼单抗且无ETS患者mPFS和mOS分别为7.7和18.7个月,DoR<34%患者分别为6.5和18个月。
  • 联合PRESSING panel与反应动力学可分层PFS(ETS和DoR的p均<0.001)和OS(ETS p<0.001,DoR p=0.017)。

关键数值与推荐

  • ETS定义为靶病灶总和缩小≥20%。
  • DoR≥34%为与生存相关的阈值。

临床怎么用

  • 在抗EGFR维持治疗降阶梯决策中,可结合ETS和DoR预判结局。
  • 影像学反应差的患者可考虑入组交叉策略试验。
  • ETS和DoR作为体内药物敏感性标志物,可整合患者和肿瘤因素指导初始治疗时长和强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown. The Valentino study showed inferior PFS in 229 RAS wild-type mCRC patients randomized to panitumumab plus FOLFOX followed by maintenance with panitumumab vs. panitumumab + 5-FU/LV. PATIENTS AND METHODS: After blinded independent central review of ETS (≥20% reduction of the sum of target lesions) and DoR in patients enrolled in Valentino, the prognostic and predictive role of such parameters was investigated, along with their combination with PRESSING panel (uncommon genomic alterations associated with anti-EGFRs resistance beyond RAS and BRAF). RESULTS: One hundred and ninety-six patients were included (ETS in 132 [67.3%], median DoR: 44.1%). Both ETS and DoR ≥34% were associated with longer mPFS (p = 0.010 and p < 0.001) and mOS (p = 0.006 and p < 0.001). The PFS benefit of 5-FU/LV added to panitumumab maintenance, reported in the study, was independent from ETS and DoR status (interaction tests NS for both PFS and OS). However, outcomes were extremely poor in patients who received single-agent panitumumab and had no-ETS (mPFS and mOS: 7.7 and 18.7 months) or DoR < 34% (mPFS and mOS: 6.5 and 18 months). Combining PRESSING panel ('molecular hyperselection') and response dynamics allowed to stratify both PFS (p < 0.001 and p < 0.001 for ETS and DoR, respectively) and OS (p < 0.001 and p = 0.017 for ETS and DoR, respectively). CONCLUSIONS: ETS and DoR allow on-treatment anticipation of outcomes following an anti-EGFR-based strategy planning de-escalation, and poor radiological response may guide enrolment in crossover strategy trials. As in vivo markers of drug sensitivity, ETS and DoR may be integrated with several patient- and tumor-related factors to wisely drive decision-making on upfront treatment duration and intensity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Manca P, Corallo S, Randon G, et al. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2020. PMID: 33321462. doi:10.1016/j.ejca.2020.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。